Flotetuzumab is a bispecific DART antibody targeting CD123 on tumor cells and CD3ε on T-cells to stimulate immune cell-mediated tumor lysis. It is being developed for the treatment of hematological malignancies by enhancing T-cell responses against CD123-expressing tumors. M.W 58.91 kDa